

[HOME](#)[ABOUT US](#)[PRODUCTS](#)[RESPONSIBILITY](#)[CAREERS](#)[Company Overview](#)[Company History](#)[Management Team](#)[Location](#)**-How we got here-**

Shionogi Inc.'s history and future are deeply intertwined with our parent company, Shionogi & Co., Ltd.

Shionogi's Global Mission

Shionogi strives constantly to supply the best possible medicine to protect the health and wellbeing of the patients we serve.

The following events are some of our company's key milestones:

A Strong Foundation

- 1878 - Gisaburo Shiono founds drug wholesaling business
- 1892 - Shionogi begins manufacturing chemicals
- 1909 - First pharmaceutical product, Antacidin, launches
- 1949 - Stocks listed on Security Exchange of Tokyo and Osaka
- 2001 - Joint venture, Shionogi-GlaxoSmithKline Pharmaceuticals LLC, established, under whose auspices the HIV integrase inhibitor dolutegravir was discovered and developed
- 2003 - US approval of rosuvastatin calcium, marketed under the brand name "Crestor" by Astra Zeneca
- 2011 - Opening of new integrated drug discovery research facility, SPRC (Shionogi Pharmaceutical Research Center)

Shionogi in the US

- 1992 - Acquisition of capsule business from Eli Lilly & Co. and established Shionogi Qualicaps, Inc.
- 2001 - Shionogi USA established to support the clinical development and regulatory progress of Shionogi's compounds in the US in Florham Park, N.J.
- 2005 - Shionogi Qualicaps, Inc. divested to focus on ethical pharmaceutical business
- 2008 - Acquisition of Sciele Pharma Inc., based in Atlanta, GA, representing Shionogi's first platform for US commercialization
- 2010 - All US commercial and development activities combined into one company, Shionogi Inc., headquartered in Florham Park, NJ
- 2011 - Acquisition of the marketed products of Victory Pharma, Inc. including their lead marketed pain product, Naprelan.
- 2012 - The new drug application for ospemifene, Shionogi's first US filing for a new chemical entity, is accepted for review by the U.S. Food and Drug Administration

Shionogi's further global presence

- 2011 - Acquisition of C&O Pharmaceutical Technology Holdings as Shionogi's subsidiary in China
- 2012 - 48th anniversary of Taiwan Shionogi, which was established in 1963
- 2012 - Establishment of development subsidiary in the EU, Shionogi Limited, based in London, UK

PRESS RELEASES**02/26/2013**

Shionogi Receives FDA Approval for Osphena™ (ospemifene)

01/08/2013

Shionogi & Co., Ltd. files patent infringement action in the U.S. District Court in New Jersey on December 28, 2012, regarding Sandoz's submission of an Abbreviated New Drug Application with the FDA seeking approval for a generic version of Doribax(r)



SHIONOGI INC.

©Shionogi Inc.

300 Campus Drive Florham Park, NJ 07932

All Rights Reserved

[Privacy Policy](#) | [Terms of Use](#)**Contact Shionogi**

For medical inquiries, call 1.800.849.9707

MERCK EXHIBIT 2093***Gnosis v Merck & Cie*****IPR2013-00117****HOF-000043**